NWBO — Northwest Biotherapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $443.51m
- $519.52m
- $1.38m
Annual cashflow statement for Northwest Biotherapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -530 | 179 | -105 | -62.6 | -83.8 |
| Depreciation | |||||
| Non-Cash Items | 498 | -220 | 43.8 | 11.1 | 15 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.035 | 2.73 | 7.21 | -3.69 | 10 |
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Cash from Operating Activities | -32.1 | -38.3 | -52.8 | -53.6 | -57 |
| Capital Expenditures | -6.61 | -6.01 | -2.9 | -3.44 | -1.01 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -1.53 | — | — | — | — |
| Acquisition of Business | |||||
| Cash from Investing Activities | -8.14 | -6.01 | -2.9 | -3.44 | -1.01 |
| Financing Cash Flow Items | — | 0.25 | 2.57 | 4.96 | 0.25 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 52.7 | 48.1 | 42 | 52.8 | 56.8 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 9.61 | 5.19 | -8.2 | -4.84 | 0.049 |